52.24
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
TradingKey - TradingKey
Why Haemonetics Stock Is Dropping So Sharply - TipRanks
Why Haemonetics (HAE) Is Down 9.5% After Mixed FY26 Results And FY27 Outlook Reset - simplywall.st
Haemonetics Q4 Earnings Call Highlights - sharewise.com
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript - Insider Monkey
A Look At Haemonetics (HAE) Valuation After Q4 Loss And Sector-Wide Medical Device Sell Off - simplywall.st
Haemonetics Earnings Call Highlights Growth Amid Headwinds - TipRanks
HAE Maintained by JP Morgan -- Price Target Lowered to $62.00 - GuruFocus
J.P. Morgan Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $62 - 富途牛牛
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Cuts Target Price to $67 - 富途牛牛
Haemonetics (HAE) Q4 2026 Earnings Transcript - AOL.com
Haemonetics Corporation Q4 2026 Earnings Call Summary - Yahoo Finance
Haemonetics (HAE) Reports Q4 Fiscal 2026 Revenue Growth and Posi - GuruFocus
Needham Maintains Haemonetics(HAE.US) With Hold Rating - 富途牛牛
Haemonetics (HAE) One Off Loss And Margin Hit Challenge Bullish Earnings Narrative - simplywall.st
Haemonetics Q4 FY2026 slides: earnings beat caps transformation plan - Investing.com
Earnings call transcript: Haemonetics Q4 2026 beats EPS forecast, stock surges - Investing.com
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27 - TipRanks
Haemonetics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Why Haemonetics Stock Is Sliding Despite Bold Outlook - TipRanks
Q4 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics beats Q4 estimates, stock surges on guidance By Investing.com - Investing.com South Africa
Haemonetics beats Q4 estimates, stock surges on guidance - Investing.com
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates - Yahoo! Finance Canada
Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Net Revenue $346.4M, vs. FactSet Est of $336.8M - marketscreener.com
Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Adjusted EPS $1.29, vs. FactSet Est of $1.27 - marketscreener.com
HAEMONETICS ($HAE) Releases Q4 2026 Earnings - Quiver Quantitative
Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026 - Yahoo Finance
Haemonetics: Fiscal Q4 Earnings Snapshot - KVUE
Haemonetics : 4th Quarter FY26 Supplemental Earnings Presentation - marketscreener.com
[8-K] HAEMONETICS CORP Reports Material Event - Stock Titan
Haemonetics puts quarterly results online before May 7 investor call - Stock Titan
Haemonetics earnings ahead: Can vascular closure rebound? By Investing.com - Investing.com Canada
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
MSN Money - MSN
Haemonetics to Present at Bank of America 2026 Healthcare Conference - PR Newswire
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape - Markets Mojo
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Swings? - simplywall.st
Earnings Preview: Haemonetics to Report Financial Results Pre-market on May 07 - 富途牛牛
Haemonetics Announces Upcoming Departure of Longtime Board Director - TipRanks
Haemonetics director Charles J. Dockendorff not standing for re-election - TradingView
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vanguard reports 2.60M-share stake in Haemonetics (HAE) via Schedule 13G - Stock Titan
North Peak Capital Management, LLC's Haemonetics Corp(HAE) Holding History - GuruFocus
Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative - Yahoo Finance
Skylands Capital LLC Sells 44,894 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Will VASCADE MVP XL’s Expanded FDA Labeling and Study Data Change Haemonetics' (HAE) Interventional Narrative? - simplywall.st
Riverwater Sees Haemonetics Volatility As Plasma Gains Test Execution - simplywall.st
Peregrine Capital Management LLC Invests $2.29 Million in Haemonetics Corporation $HAE - MarketBeat
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures - PR Newswire
574-patient study reports 0% bleeding with Haemonetics closure device - Stock Titan
Riverwater Partners Analyzes Haemonetics Performance in Q1 2026 Letter - HarianBasis.co
Boston Trust Walden Corp Sells 376,040 Shares of Haemonetics Corporation $HAE - MarketBeat
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation - Yahoo Finance
Haemonetics Corp stock (US4041191090): Why mobile-first Discover changes matter more now for medtech - AD HOC NEWS
Is Haemonetics (HAE) Using VASCADE MVP XL’s Expanded FDA Label To Deepen Its Moat? - simplywall.st
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):